Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1091 Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1092

CEO Statement

Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1091 Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1092
Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1091 Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1092

“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinical development, and in addition, Alligator increased its focus on the co-stimulatory receptor 4-1BB with a co-development partnership agreement with Aptevo Therapeutics Inc. on the bispecific antibody ALG.APV-527. Our pipeline is now stronger than ever with four candidates for tumor-directed immunotherapy in clinical and pre-clinical development” said Per Norlén, CEO.
Read more